Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 9, 2025Frontiers in MedicineOpen Access

Sequential tyrosine kinase inhibitor therapy for EGFR L747P-mutated lung adenocarcinoma in a renal transplant recipient: a 24-month case report

View Full Paper
Ask AI
Bookmark
Share

Authors

WXWenxiu XieFCFeng ChenZLZhang Lei

Discussion

Loading...

Member takes

Overview

Case report describes treatment of lung adenocarcinoma in a renal transplant recipient, highlighting TKI efficacy and challenges.

Key Points

  • The patient experienced an overall survival of 24 months due to sequential TKI therapy.
  • Progression-free survival rates were 9 months for gefitinib, 4.5 months for osimertinib, and 2.5 months for dacomitinib.
  • This case illustrates successful management of lung adenocarcinoma with EGFR L747P mutation in a kidney transplant recipient.
  • The findings emphasize the need for careful cancer surveillance and individualized TKI strategies in transplant patients.

Cite This Study

Xie et al. (2025) studied this question.

synapsesocial.com/papers/68e79cf2ed88661f66c2e11ahttps://doi.org/10.3389/fmed.2025.1651584
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Dynamic therapeutic response to osimertinib and immunotherapy in an EGFR L747S and L858R co-mutant NSCLC2026
  2. 2SUCCESSFUL TREATMENT OF METASTATIC LUNG ADENOCARCINOMA WITH LAZERTINIB: A CASE REPORT2024
  3. 3The Efficacy of Adjuvant EGFR-TKI Therapy for Stage IA Lung Adenocarcinoma with EGFR Mutations: A Retrospective Cohort Study2026
  4. 4Simultaneous Acquisition of T790M Mutation and SCLC Transformation during Targeted Therapy in EGFR-Mutated Lung Adenocarcinoma: A Rare Case Report2024 · 2 citations
  5. 5EGFR exon 18 delE709_T710insD mutated stage IV non-small cell lung cancer treated with osimertinib: a case report2024 · 1 citations